Abstract:Aim: To compare the effect, safety and tolerance of citalopram and venlafaxine for depressive disorder. Methods: The patients, who were tre ated at the out-patient clinic or hospitalization, Center of Mental Health, Renmin Hospital, Wuhan University from October 2003 to October 2004,were divided randomly into 2 groups. Those in the citalopram group with 32 cases were treated with 20-40 mg citalopram per day; Those in the venlafaxine group with 34 cases were treated with 150-225 mg venlafaxine per day for six weeks. Before treatment and at the end of 1st, 2nd, 4th and 6th of treatment, they were assessed by the Hamilton Depression Rating Scale (totally 17 items, the 5 grades score of 0-4 points, 0 point for without this symptom, 4 points for severe), Clinical global impression scale (CGIS) (8 grade score of 0-7 points, 0 point for without disease, 7 points for severe) and Treatment Emergent Symptom Scale (TESS) (5 grade score of 0-4 points, 0 point for without this symptom, 4 points for severe). The effects were assessed by the Hamilton depression rating scale to perform division of reducing score rate, ≥ 25% for effective, ≥ 50% for significant effect, ≥ 75% for recovery. The CGIS was used to divide, ≤ 2 for effective, ≤ 1 for recovery. Results: One in the citalopram group was withdrew at the end of the 4th week; Two in the venlafaxine group, one was at the end of the 2nd week, the other was moved back because of bad reaction. Totally 63 cases were finished the 6-week observation, 31 cases in the citalopram group, 32 cases in the venlafaxine group. (1) Comparison of the scores of Hamilton depression rating scale and CGIS before and after the treatment in the two groups: The comparison of reducing score value of the general score of Hamilton depression rating scale and score of CGIS after treatment in two groups showed that at the end of 2nd and 4th week were bigger in the venlafaxine group than that in the citalopram group (17.47±5.26, 24.33± 6.32; 12.13±5.87, 19.73±6.24; 3.73±1.03, 4.66±0.89; 3.26±1.03, 4.06 ±0.79, P < 0.01, P < 0.05). (2) Comparison of effects in the two groups: The reducing score rate of general score of Hamilton depression rating scale at the end of the 6th week showed that the efficiency, significant effect and recovery rate in the citalopram group and the venlafaxine group was similar (94%, 94%; 68%, 72%; 13%, 25%). The efficiency and recovery rate in the citalopram group by the CGIS were similar (81 %, 84%; 42%, 53%). (3) Comparison of bad reaction incidence: It was lower in the citalopram group than that in the venlafaxine group (13%, 47%, P=0.005). Conclusion: The citalopram and venlafaxine have similar effects on the treatment of depressive disorder, and the response of the venlafaxine occurres earlier than that of the citalopram. They all have good safety, and there are fewer and slighter side effects of citalopram compared with the venlafaxine.

Efficacy and safety of venlafaxine extended release versus paroxetine for depression:a meta-analysis

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study

Venlafaxine vs clomipramine in treating major depression associated with anxiety

Treatment of Depressive Outpatient with Venlafaxine:An Open Clinical Trial

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

A parallel control study of venlafaxine and fluoxertine in first-episode patients with depression

Expert consensus for clinical appliance of venlafaxine controlled release formulation

A Randomized Double-Blind Controlled Clinical Trail of Venlafaxine Sustained Release Tablets Vs.sustained-Release Capsules in Treatment of Major Depression Disorder

A Meta-analysis of Efficacy and Adverse Reactions of Paroxetine and Fluoxetine in Patients with Depression

Efficacy and safety of enteric-coted sustained release tablets in the treatment of major depression

Comparison of citalopram and venlafaxine for depressive disoder

Venlafaxine in treating 62 patients with depression: a multicenter open trial

The Efficacy and Safety of Mirtazapine and Fluoxetine for Depression:A Meta-analysis

Control Study of Venlafaxine and Fluoxetine in Treatment of First-episode Depression

Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression: a Double-Blind, Randomized Pilot Study in a Chinese Population.

Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study

Venlafaxine Vs. Paroxetine in the Acute Phase of Treatment for Major Depressive Disorder among Han Chinese Population in Taiwan

Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study

A Randomized and Double-Blind Clinical Trial of Venlafaxine Hydrochloride Sustained Release Capsules for Treating Juvenile Depression

A control study of Escitalopram and Venlafaxine in senile depression

Effectiveness and Safety of Escitalopram and Duloxetine in the Treatment of Depression:a Meta-analysis